These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500 [TBL] [Abstract][Full Text] [Related]
4. NFATc1 as a therapeutic target in FLT3-ITD-positive AML. Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987 [TBL] [Abstract][Full Text] [Related]
5. Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy. Wang F; Liu Z; Zeng J; Zhu H; Li J; Cheng X; Jiang T; Zhang L; Zhang C; Chen T; Liu T; Jia Y Leuk Res; 2015 Dec; 39(12):1421-7. PubMed ID: 26505133 [TBL] [Abstract][Full Text] [Related]
6. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity. Yi H; Zeng D; Shen Z; Liao J; Wang X; Liu Y; Zhang X; Kong P Oncotarget; 2016 Jun; 7(26):40387-40397. PubMed ID: 27248172 [TBL] [Abstract][Full Text] [Related]
7. Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation. Huang A; Ju HQ; Liu K; Zhan G; Liu D; Wen S; Garcia-Manero G; Huang P; Hu Y Cancer Lett; 2016 Jul; 377(2):149-57. PubMed ID: 27132990 [TBL] [Abstract][Full Text] [Related]
8. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014 [TBL] [Abstract][Full Text] [Related]
9. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792 [TBL] [Abstract][Full Text] [Related]
10. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205 [TBL] [Abstract][Full Text] [Related]
11. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo. Ma HS; Greenblatt SM; Shirley CM; Duffield AS; Bruner JK; Li L; Nguyen B; Jung E; Aplan PD; Ghiaur G; Jones RJ; Small D Blood; 2016 Jun; 127(23):2867-78. PubMed ID: 27103744 [TBL] [Abstract][Full Text] [Related]
12. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation. Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603 [No Abstract] [Full Text] [Related]
13. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells. Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583 [TBL] [Abstract][Full Text] [Related]
14. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. Nguyen B; Williams AB; Young DJ; Ma H; Li L; Levis M; Brown P; Small D Oncotarget; 2017 Feb; 8(7):10931-10944. PubMed ID: 28077790 [TBL] [Abstract][Full Text] [Related]
15. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109 [TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014 [TBL] [Abstract][Full Text] [Related]
17. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML. Man CH; Lam SS; Sun MK; Chow HC; Gill H; Kwong YL; Leung AY Blood; 2014 Apr; 123(16):2530-9. PubMed ID: 24608976 [TBL] [Abstract][Full Text] [Related]
18. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502 [TBL] [Abstract][Full Text] [Related]
19. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. Lindblad O; Cordero E; Puissant A; Macaulay L; Ramos A; Kabir NN; Sun J; Vallon-Christersson J; Haraldsson K; Hemann MT; Borg Å; Levander F; Stegmaier K; Pietras K; Rönnstrand L; Kazi JU Oncogene; 2016 Sep; 35(39):5119-31. PubMed ID: 26999641 [TBL] [Abstract][Full Text] [Related]
20. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]